MPS Pharmaa FY26 Net Loss ₹101.22 Lacs; Auditor's Modified Opinion

MPS Pharmaa Limited's Board approved its standalone audited financial results for the quarter and financial year ended March 31, 2026. For FY26, the company reported a total comprehensive loss of ₹101.22 Lacs, widening from ₹88.81 Lacs in FY25, with an EPS of (0.53). The auditors issued a modified opinion, citing inability to verify investments worth ₹53.80 Lacs and concerns over stalled Capital Work in Progress of ₹2.41 Crore. The company explained that investment share certificates were misplaced and construction was temporarily suspended. M/s Sanghi & Co. was re-appointed as Internal Auditor. The company's drug manufacturing license renewal is pending, and it is actively seeking to restart business operations. Trading of its shares on BSE remains suspended due to unpaid Annual Listing Fees since FY21-22, with limited trading allowed on a trade-for-trade basis.